FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Codon topics
Hydrocodone
Nucleic Acid
Acetaminophen
Carboxylic Acid
Benzoic Acid
Genetically
Recombinant
Amino Acid
Nucleotide
Reverse Transcriptase Inhibitors
Reverse Transcriptase Inhibitor
Reverse Transcriptase
Antibodies
Base Sequence
Replication

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Codon patents



      
           
This page is updated frequently with new Codon-related patent applications. Subscribe to the Codon RSS feed to automatically get the update: related Codon RSS feeds. RSS updates for this page: Codon RSS RSS


Date/App# patent app List of recent Codon-related patents
02/26/15
20150056654
 Process for the purification of recombinant albumin patent thumbnailnew patent Process for the purification of recombinant albumin
A process is provided for the preparation of a highly pure albumin solution the process comprising subjecting albumin (preferably expressed and secreted by transformed yeast) to a series of chromatographic steps. Preferably, the process comprises the steps of positive mode cation exchange chromatography, positive mode anion exchange chromatography, positive mode affinity chromatography, negative mode affinity chromatography (preferably using immobilised aminophenylboronic acid), negative mode cation exchange chromatography, and negative or positive mode anion exchange chromatography.
Novozymes Biopharma Dk A/s
02/26/15
20150056230
 Equine encephalitis virus vaccines and methods of using thereof patent thumbnailnew patent Equine encephalitis virus vaccines and methods of using thereof
Disclosed herein are nucleotide sequences which encode a plurality of structural proteins, except the capsid, of an equine encephalitis virus, wherein the nucleotide sequence is codon-optimized for mammalian expression. The nucleotide sequences are codon-optimized for expression in humans.
02/19/15
20150051251
 Premature-termination-codons readthrough compounds patent thumbnailPremature-termination-codons readthrough compounds
Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided.. .
The Regents Of The University Of California
02/19/15
20150050339
 Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone,  making and use thereof patent thumbnailPhenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, making and use thereof
The presently described technology provides phenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a salt thereof, a derivative thereof or a combination thereof chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs or compositions of hydrocodone which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology..
Kempharm, Inc.
02/12/15
20150045383
 Treating pain in patients with hepatic impairment patent thumbnailTreating pain in patients with hepatic impairment
An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.
Zogenix, Inc.
02/12/15
20150044282
 Abuse resistant forms of immediate release oxycodone,  use and  making patent thumbnailAbuse resistant forms of immediate release oxycodone, use and making
An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (gi) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided..
Inspirion Delivery Technologies, Llc
02/12/15
20150044247
 Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses patent thumbnailComputationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
Described herein is the generation of optimized h3n2, h2n2 and b influenza ha polypeptides for eliciting a broadly reactive immune response to influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on h3n2, h2n2 and b influenza isolates.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
02/05/15
20150037409
 Controlled release hydrocodone formulations patent thumbnailControlled release hydrocodone formulations
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.
01/22/15
20150026834
 Anastasis biosensor patent thumbnailAnastasis biosensor
The present invention relates to the field of anastasis, i.e., the process of reversal of apoptosis. More specifically, the present invention provides methods and compositions useful for studying anastasis.
The Johns Kopkins University
01/22/15
20150025044
 Identification and use of compounds that affect the fidelity of eukaryotic translation initiation codon selection patent thumbnailIdentification and use of compounds that affect the fidelity of eukaryotic translation initiation codon selection
A screening method for identifying compounds that alter the fidelity with which the initiation codon in mrnas is recognized by the translational apparatus in eukaryotes is disclosed. This screening method was used to identify compounds having such activity.
The Johns Hopkins University
01/22/15
20150024438

Heterologous expression of termite cellulases in yeast


The present invention provides for heterologous expression of termite and termite-associated symbiont cellulases. The cellulases can, for example, be codon-optimized and expressed in yeast host cells, such as the yeast saccharomyces cerevisiae.
Mascoma Corporation
01/15/15
20150017196

Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses


Described herein is the generation of optimized h5n1 and h1n1 influenza ha polypeptides for eliciting a broadly reactive immune response to influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on h5n1 and h1n1 influenza isolates.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
01/08/15
20150010945

Methods and systems for tracking bioremediation processes


A method for expression of engineered constructs containing sequences coding for functional genes of interest in e. Coli strains.
Arizona State Board Of Regents For And On Behalf Of Arizona State University
01/01/15
20150005249

Readthrough inducing agent and drug for treating genetic disease caused by nonsense mutation


A readthrough inducing agent for inducing readthrough of a premature stop codon generated by nonsense mutations, the readthrough inducing agent comprising a compound having a structure expressed by the following structural formula (a), and a drug for treating a genetic disease caused by nonsense mutations, the drug comprising the readthrough inducing agent.. .
University Of Tokyo
12/25/14
20140378498

Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia


The present disclosure provides an extended release pharmaceutical composition comprising hydrocodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof..
Mallinckrodt Llc
12/25/14
20140378496

Opioid analgesics and 3-hydroxyacetanilide for treating pain


Pharmaceutical combinations of opioid analgesics and analgesics that act through non-opioid mechanisms are commonly used to provide pain relief. An example of this pharmaceutical combination is the product vicodin™, where the opioid analgesic is hydrocodone and the non-opioid is acetaminophen.
Slx Pharmaceuticals, Llc
12/25/14
20140377800

Method for achieving improved polypeptide expression


The present invention relates to methods of optimization of a protein coding sequences for expression in a given host cell. The methods apply genetic algorithms to optimise single codon fitness and/or codon pair fitness sequences coding for a predetermined amino acid sequence.
Dsm Ip Assets B.v.
12/25/14
20140377349

Controlled release oral dosage form comprising oxycodone


The present invention relates to a controlled-release oral dosage form for administration of oxycodone once a day and a method of preparing a controlled-release oral dosage form for administration of oxycodone once a day.. .
Develco Pharma Schweiz Ag
12/25/14
20140377348

Controlled release hydrocodone formulations


A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a c12/cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours..
Purdue Pharma L.p.
12/18/14
20140371132

Codon signature for neuromyelitis optica


The present invention provides for the diagnosis and prediction of neuromyelitis optica (nmo) in subject utilizing a unique a codon signature in b cells that has now been associated with nmo and not with any other autoimmune disease. More particularly, the method may comprise the steps of (a) providing a 10 b-cell containing sample from a subject, or dna or rna isolated therefrom; (b) determining the vh1 and/or vh4 structure of vh1nh4-expressing b-cells from said subject, (c) determining the mutational frequency vh1 and/or vh4 genes; (d) identifying the presence or absence of a codon signature associated with nmo or risk of nmo; and (e) selecting patients exhibiting said codon signature..
The Board Of Regents Of The University Of Texas System
12/18/14
20140370545

Reengineering mrna primary structure for enhanced protein production


Described herein are rules to modify natural mrnas or to engineer synthetic mrnas to increase their translation efficiencies. These rules describe modifications to mrna coding and 3′ utr sequences intended to enhance protein synthesis by: 1) decreasing ribosomal diversion via aug or non-canonical initiation codons in coding sequences, and/or 2) by evading mirna-mediated down-regulation by eliminating one or more mirna binding sites in coding sequences..
The Scripps Research Institute
12/04/14
20140357531

Method for producing a nucleic acid library having at least two adjacent variable codon triplets


The invention relates to a method for producing a dna sequence for a nucleic acid library having a plurality of elements. The synthesized dna sequence comprises at least three sections.
12/04/14
20140356962

Novel attenuated poliovirus: pv-1 mono-cre-x


A novel and stable attenuated poliovirus is produced by engineering an indigenous replication element (cre), into the 5′ non-translated genomic region (with inactivation of the native ere element located in the coding region of 2c (mono-crepv), and replacing the nucleic acid sequence of all or part of the capsid coding region (pi) with a substitute pi coding region having reduced codon pair bias. The stably attenuated poliovirus is effective for vaccines and immunization..
12/04/14
20140356390

Modulation of replicative fitness by deoptimization of synonymous codons


Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen.
11/27/14
20140350089

Optimized messenger rna


The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons..
11/20/14
20140343009

Methods for treating methylmalonic acidemia


Methods for treating methylmalonic acidemia in which at least one allele of a gene associated with mma (e.g., the mut, mmaa, or mmab gene) contains a mutation (e.g., nonsense mutation) that results in a premature stop codon in rna encoded by an allele of the gene associated with mma involving the administration of a compound that promotes readthrough of rna (e.g., messenger rna) containing a premature stop codon encoded by an allele of the gene associated with mma are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment..
11/20/14
20140342451

Methods of incorporating amino acid analogs into proteins


The invention provides a method of incorporating nonstandard amino acids into a protein by utilizing a modified aminoacyl-trna synthetase to charge the nonstandard amino acid to a modified trna, which forms strict watson-crick base-pairing with a codon that normally forms wobble base-pairing with natural trnas.. .
11/06/14
20140329711

Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same


A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon.
11/06/14
20140328935

Genes encoding major capsid protein l1 of human papilloma virus


The present invention discloses a codon-optimized gene encoding major capsid protein l1 of human papilloma virus, which is capable, after transduced into a yeast cell, of efficiently expressing the major capsid protein l1 of human papilloma virus. The present invention also discloses an immunogenic macromolecule which is essentially produced by expression of said codon-optimized gene encoding the major capsid protein l1 of human papilloma virus in a yeast cell.
10/23/14
20140315276

Synthesis of linear and branched polymers of polypeptides through direct conjugation


Methods are provided for a one step synthesis of polypeptide polymers or co-polymers. The polymers or co-polymers can be linear or branched.
10/16/14
20140309142

Method of on-chip nucleic acid molecule synthesis


A method of synthesizing a nucleic acid molecule, such as a gene, on a substrate or microchip is described. In particular, a method for synthesizing, amplifying, and assembling dna oligonucleotides into a nucleic acid molecule or gene product, on a single substrate or microchip is described.
10/16/14
20140308349

Pharmaceutical compositions


Methods and compositions are provided which comprise effective amounts of one or more analgesics, such as hydrocodone or acetaminophen, and an antiemetic, such as promethazine, to treat a subject, including reducing or eliminating an adverse effect associated with the analgesics.. .
10/09/14
20140303073

Antisense antiviral compound and treating influenza viral infection


The present invention relates to antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal.
10/02/14
20140296321

Methods and compositions for manipulating translation of protein isoforms from alternative initiation of start sites


Provided herein are antisense oligonucleotides, compositions comprising antisense oligonucleotides, and methods for the use of antisense oligonucleotides in manipulating translation. Expression of isoforms of proteins expressed from different start codons of the same transcript are inhibited by antisense oligonucleotides, which may also enhance expression of non-target isoforms..
10/02/14
20140296277

Pharmaceutical preparation containing oxycodone and naloxone


The invention concerns a storage stable pharmaceutical preparation comprising oxycodone and naloxone for use in pain therapy, with the active compounds being released from the preparation in a sustained, invariant and independent manner.. .
10/02/14
20140296137

Methods and compositions for controlling rotifers


Described herein are compositions and methods for controlling, inhibiting, reducing and/or preventing rotifer growth with antimicrobial peptides. Methods for removing and/or preventing rotifer infestations in algae cultivations by controlling, inhibiting, reducing and/or preventing rotifer growth with an antimicrobial peptide (amp) are further provided.
10/02/14
20140295006

Herbal composition for treating metastatic breast cancer


The invention provides a composition comprising a mixture of extracts obtained from atractylodes macrocephala, astragalus membranaceus, taraxacum mongolicum, poria cocos, ligusticum chuanxiong, ligustrum lucidum, codonopsis pilosula, glycyrrhiza uralensis, hedyotis diffusa, pseudostellaria heterophylla, and viola philippica. The present invention further provides a method for treating metastatic breast cancer in a subject in need thereof, comprising: administering to said subject an pharmaceutically effective amount of the composition..
09/25/14
20140288113

Extended release compositions comprising hydrocodone and acetaminophen for rapid onset and prolonged analgesia that may be administered without regard to food


The present disclosure provides an extended release pharmaceutical composition comprising hydrocodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof..
09/25/14
20140288006

Ptd-smad7 therapeutics


The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described.
09/25/14
20140287528

Incorporation of methyl lysine into polypeptides


The invention relates to a method of making a polypeptide comprising at least one nε-methyl-lysine at a specific site in said polypeptide, said method comprising (a) genetically directing the incorporation of r—nε-methyl-lysine into said polypeptide, wherein r comprises an auxiliary group; and (b) catalysing the removal of r from the polypeptide of (a). In particular the invention relates to such a method wherein genetically directing the incorporation of r—nε-methyl-lysine into said polypeptide comprises arranging for the translation of a rna encoding said polypeptide, wherein said rna comprises an amber codon, and wherein said translation is carried out in the presence of an amber trna charged with r—nε-methyl-lysine..
09/18/14
20140275143

Compositions comprising an opioid and an additional active pharmaceutical ingredient for rapid onset and extended duration of analgesia that may be administered without regard to food


The present disclosure provides pharmaceutical compositions comprising an opioid and an additional active pharmaceutical ingredient, wherein the composition exhibits gastric retentive properties which are achieved by a combination of a physical property of the composition and release of the opioid, wherein upon administration to a subject, the composition has at least one pharmacokinetic parameter that differs by less than about 30% when the subject is in a fasted state as compared to a fed state. The present disclosure further provides pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval.
09/18/14
20140271840

Controlled release hydrocodone formulations


A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a c12/cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours..
09/18/14
20140271602

Nucleotide-specific recognition sequences for designer tal effectors


The invention relates to methods of altering expression of a genomic locus of interest or specifically targeting a genomic locus of interest in an animal cell, which may involve contacting the genomic locus with a non-naturally occurring or engineered composition that includes a deoxyribonucleic acid (dna) binding polypeptide having a n-terminal capping region, a dna binding domain comprising at least five or more transcription activator-like effector (tale) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest, and a c-terminal capping region, wherein the polypeptide includes at least one or more effector domains, and wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to the dna of the genomic locus.. .
09/11/14
20140255343

Dna vaccine, inducing the immune response, immunisation, antibodies specifically recognising the h5 haemagglutinin of an influenza virus and use of the dna vaccine


The object of the invention is a dna vaccine, method of inducing the immune response, antibodies specifically recognising the haemagglutinin h5 of an influenza virus and application of the dna vaccine. According to the invention, one or two-fold immunisation of hens with dna vaccine containing a cdna encoding the modified h5 haemagglutinin ha protein, i.e.


Popular terms: [SEARCH]

Codon topics: Hydrocodone, Nucleic Acid, Acetaminophen, Carboxylic Acid, Benzoic Acid, Genetically, Recombinant, Amino Acid, Nucleotide, Reverse Transcriptase Inhibitors, Reverse Transcriptase Inhibitor, Reverse Transcriptase, Antibodies, Base Sequence, Replication

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Codon for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Codon with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         









0.2406

3091

2 - 1 - 72